Treatment Strategies in Neutrophilic Dermatoses: A Comprehensive Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Nov 14

PMID 37958609

Authors

Grisell Starita-Fajardo

David Lucena-Lopez

Maria Asuncion Ballester-Martinez

Montserrat Fernandez-Guarino

Andres Gonzalez-Garcia

Affiliations

Soon will be listed here.

Abstract

Neutrophilic dermatoses (NDs) are a group of noninfectious disorders characterized by the presence of a sterile neutrophilic infiltrate without vasculitis histopathology. Their physiopathology is not fully understood. The association between neutrophilic dermatoses and autoinflammatory diseases has led some authors to propose that both are part of the same spectrum of diseases. The classification of NDs depends on clinical and histopathological features. This review focuses on the recent developments of treatments in these pathologies.

Citing Articles

Hydroxychloroquine-induced Sweet's Syndrome: A Case Report and Literature Review.

Almeida-Silva G, Antunes J, Tribolet de Abreu I, Monteiro F, Vasconcelos P, Soares-Almeida L Acta Derm Venereol. 2025; 105():adv41333.

PMID: 39780415 PMC: 11736664. DOI: 10.2340/actadv.v105.41333.

References

Marzano A, Ishak R, Saibeni S, Crosti C, Meroni P, Cugno M . Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013; 45(2):202-10. DOI: 10.1007/s12016-012-8351-x. View

Ormerod A . Epidemiology, comorbidities and mortality of pyoderma gangrenosum: new insights. Br J Dermatol. 2021; 185(6):1089-1090. DOI: 10.1111/bjd.20713. View

Fimmel S, Zouboulis C . Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2011; 2(1):9-16. PMC: 3084959. DOI: 10.4161/derm.2.1.12490. View

Nousari Y, Wu B, Valenzuela G . Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome. Clin Exp Dermatol. 2021; 46(7):1330-1332. DOI: 10.1111/ced.14712. View

Ingram J, Collier F, Brown D, Burton T, Burton J, Chin M . British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2018; 180(5):1009-1017. DOI: 10.1111/bjd.17537. View

Skendros P, Papagoras C, Lefaki I, Giatromanolaki A, Kotsianidis I, Speletas M . Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition. Br J Dermatol. 2016; 176(1):212-215. DOI: 10.1111/bjd.14685. View

Seminario-Vidal L, Guerrero C, Sami N . Refractory Sweet's syndrome successfully treated with rituximab. JAAD Case Rep. 2016; 1(3):123-5. PMC: 4808708. DOI: 10.1016/j.jdcr.2015.03.002. View

Ben Abdallah H, Fogh K, Bech R . Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review. Int Wound J. 2019; 16(2):511-521. PMC: 7949186. DOI: 10.1111/iwj.13067. View

Herberger K, Dissemond J, Bruggestrat S, Sorbe C, Augustin M . Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients. J Dtsch Dermatol Ges. 2018; 17(1):32-41. DOI: 10.1111/ddg.13741. View

10.

Jennings L, Molloy O, Quinlan C, Kelly G, OKane M . Treatment of pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) with weight-based anakinra dosing in a Hepatitis B carrier. Int J Dermatol. 2017; 56(6):e128-e129. DOI: 10.1111/ijd.13528. View

11.

Sugiura K . Role of Interleukin 36 in Generalised Pustular Psoriasis and Beyond. Dermatol Ther (Heidelb). 2022; 12(2):315-328. PMC: 8850521. DOI: 10.1007/s13555-021-00677-8. View

12.

Yamasaki K, Nakagawa H, Kubo Y, Ootaki K . Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2016; 176(3):741-751. DOI: 10.1111/bjd.14702. View

13.

de Wet J, Jordaan H, Kannenberg S, Tod B, Glanzmann B, Visser W . Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab. Dermatol Online J. 2018; 23(12). View

14.

Kimball A, Okun M, Williams D, Gottlieb A, Papp K, Zouboulis C . Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016; 375(5):422-34. DOI: 10.1056/NEJMoa1504370. View

15.

Weber I, Giefer J, Martin K . Effects of Exercise and Dietary Modifications on Hidradenitis Suppurativa: A Systematic Review. Am J Clin Dermatol. 2023; 24(3):343-357. DOI: 10.1007/s40257-023-00756-w. View

16.

Hsiao J, Antaya R, Berger T, Maurer T, Shinkai K, Leslie K . Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol. 2010; 146(11):1265-70. DOI: 10.1001/archdermatol.2010.328. View

17.

Lewandowski M, Swierczewska Z, Baranska-Rybak W . Hidradenitis suppurativa: a review of current treatment options. Int J Dermatol. 2022; 61(9):1152-1164. DOI: 10.1111/ijd.16115. View

18.

Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H . Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018; 45(5):529-539. PMC: 5947137. DOI: 10.1111/1346-8138.14294. View

19.

Zouboulis C, Desai N, Emtestam L, Hunger R, Ioannides D, Juhasz I . European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015; 29(4):619-44. DOI: 10.1111/jdv.12966. View

20.

Hashemi S, Fazeli S, Vahedi A, Golabchifard R . Rituximab for refractory subcutaneous Sweet's syndrome in chronic lymphocytic leukemia: A case report. Mol Clin Oncol. 2016; 4(3):436-440. PMC: 4774570. DOI: 10.3892/mco.2015.715. View